A Phase 0 Study of AZD1775 in Recurrent GBM Patients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

March 25, 2019

Conditions
GlioblastomaGBM
Interventions
BIOLOGICAL

AZD1775

All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.

Trial Locations (1)

85013

Barrow Neurological Institute at St. Joseph's Hospital Medical Center, Phoenix

All Listed Sponsors
collaborator

The Ben & Catherine Ivy Foundation

OTHER

collaborator

American Society of Clinical Oncology

OTHER

collaborator

Barbara Ann Karmanos Cancer Institute

OTHER

collaborator

Translational Genomics Research Institute

OTHER

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER

NCT02207010 - A Phase 0 Study of AZD1775 in Recurrent GBM Patients | Biotech Hunter | Biotech Hunter